IKA Trial: MammaPrint UltraLow & Limited Systemic Endocrine Overtreatment
IKA Trial, Breast Cancer Res Treat, 2022; 194(2): 265-278 Authors: Opdam, et al.
Read MoreBudget impact analysis for the Health Care Package by using MammaPrint in Belgium
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors De Lameillieure Read More
Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors Esther Schuler(1), Read More
MINDACT: Outcomes of any adjuvant systemic treatment in ESBC
Annals of Oncology, Volume 33, Issue 3, March 2022, Pages 310-320 Authors: Lopes Cardozo et al.
Read MoreMINDACT Trial: Outcome of Patients with UltraLow Risk, JCO 2022
Journal of Clinical Oncology, Volume 40, Number 12, January 21, 2022 Authors: Audeh et al.
Read MoreDurvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read MoreMolecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint
PUBLICATION: ASCO 2021 Authors Joyce O’Shaughnessy1, Virginia G. Read More
Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients ≤ 50 years and > 50 years
PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Read More
Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer
PUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Read More
High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer
Publication: J Surg Oncol. 2022;125:596–602. Authors: Jennifer A. Crozier, Read More
